Blueprint Medicines Corporation
NASDAQ:BPMC
83.4 (USD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Blueprint Medicines Corporation |
Symbool | BPMC |
Munteenheid | USD |
Prijs | 83.4 |
Beurswaarde | 5,283,014,700 |
Dividendpercentage | 0% |
52-weken bereik | 53.73 - 121.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Kathryn Haviland |
Website | https://www.blueprintmedicines.com |
An error occurred while fetching data.
Over Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)